Prasugrel
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anemia, Sickle Cell
Conditions
Anemia, Sickle Cell
Trial Timeline
Jul 1, 2010 → Jan 1, 2011
NCT ID
NCT01178099About Prasugrel
Prasugrel is a phase 1 stage product being developed by Daiichi Sankyo for Anemia, Sickle Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT01178099. Target conditions include Anemia, Sickle Cell.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03672097 | Approved | Completed |
| NCT01476696 | Phase 2 | Completed |
| NCT01178099 | Phase 1 | Completed |
Competing Products
20 competing products in Anemia, Sickle Cell
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aranesp® | Amgen | Approved | 84 |
| KER-047 | Keros Therapeutics | Phase 2 | 44 |
| LY2787106 | Eli Lilly | Phase 1 | 33 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| epoetin beta + placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| recombinant human erythropoietin + recombinant human erythropoietin placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| recombinant human erythropoietin + recombinant human erythropoietin | Chugai Pharmaceutical | Phase 3 | 77 |
| darbepoetin alfa | Amgen | Phase 3 | 76 |
| Prasugrel + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| Roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| Alefacept | Astellas Pharma | Phase 1 | 33 |
| Roxadustat | Astellas Pharma | Phase 2 | 52 |
| roxadustat | Astellas Pharma | Phase 1 | 33 |
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 77 |
| Roxadustat | Astellas Pharma | Pre-clinical | 23 |
| Roxadustat + Epoetin Alfa | Astellas Pharma | Phase 3 | 77 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |